Showing results (21-30 of 93) with videos related to
Sort By:
Pageof 10
The Journal of Pharmacology and Experimental Therapeutics|November 18, 2003
Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the ratAlexander Treiber, Ralph Schneiter, Stephane Delahaye, et al.Psychopharmacology|August 20, 2021
Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomniaCatherine Roch, Giorgio Bergamini, Michel A Steiner, et al.British Journal of Clinical Pharmacology|April 23, 2002
Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjectsJasper Dingemanse, Martine Clozel, Paul L M van GiersbergenJournal of Cardiovascular Pharmacology|May 22, 2002
Entry-into-humans study with tezosentan, an intravenous dual endothelin receptor antagonistJasper Dingemanse, Martine Clozel, Paul L M van GiersbergenAnnals of the New York Academy of Sciences|August 21, 2015
Development of macitentan for the treatment of pulmonary arterial hypertensionMona Selej, Alain J Romero, Richard N Channick, et al.The Journal of Pharmacology and Experimental Therapeutics|July 28, 2010
Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric functionKeith Morrison, Roland Ernst, Patrick Hess, et al.The Journal of Pharmacology and Experimental Therapeutics|November 4, 2005
The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic ratsMartine Clozel, Patrick Hess, Changbin Qiu, et al.Plos One|October 19, 2012
Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cellsJohn Gatfield, Celia Mueller Grandjean, Thomas Sasse, et al.Bioorganic & Medicinal Chemistry Letters|March 6, 2003
Bis-sulfonamides as endothelin receptor antagonistsChristoph Boss, Martin H Bolli, Thomas Weller, et al.Journal of Medicinal Chemistry|August 21, 2015
Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial HypertensionTetsuo Asaki, Keiichi Kuwano, Keith Morrison, et al.Pageof 10